Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGAV | P06756 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715869 | 0.89 | NAMPT (0.45) | NAMPTITGB3ITGAVITGA2B | |
| SCHEMBL4761347 | 0.88 | NAMPT (0.43) | NAMPTITGB3ITGAVITGA2B | |
| SCHEMBL4760275 | 0.87 | NAMPT (0.39) | NAMPTITGB3ITGAVITGA2B | |
| Hydrochloric Acid SCHEMBL4760424 | 0.87 | NAMPT (0.43) | NAMPTITGB3ITGAVITGA2B | |
| SCHEMBL4717476 | 0.83 | NAMPT (0.42) | NAMPT | |
| SCHEMBL4762054 | 0.82 | NAMPT (0.42) | NAMPTITGB3ITGAVITGA2B | |
| SCHEMBL4791224 | 0.81 | ITGAV (0.57) | ITGB3ITGAVITGA2BITGB6 | |
| SCHEMBL4789561 | 0.81 | ITGAV (0.57) | ITGB3ITGAVITGA2BITGB6 | |
| SCHEMBL4715261 | 0.80 | NAMPT (0.40) | NAMPTITGB3ITGAVITGA2B | |
| SCHEMBL4761797 | 0.79 | ITGB3 (0.53) | NAMPTITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | claimed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | claimed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |